PDCD1 and neoplasm: An essential point is that the expression of PD-L1 and Siglec-15 are mutually exclusive; therefore, Siglec-15 and the molecules that regulate its expression (such as the lncRNA LINC00973) are potential targets for tumor immunotherapy in cases where immunosuppression is not associated with PD-1/PD-L1.